Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancer

Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancer - Phase IIstudy of FOLFIRI+biweekly cetuximab

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011363

Enrollment

Registered

2013-08-03

Start date

2013-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable colorectal cancer

Interventions

administration of cetuximab biweekly

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: pathologically proven colorectal cancer Kras wild type PS; 0-2 untreated case

Exclusion criteria

Exclusion criteria: severe dysfunction of bone marrow, liver, renal, and cardiac function no prior radiotherapy, chemotherapy or any molecular targeting therapy for rectal cancer; no other co-existing malignancy or malignancy within the last five years prior to enrollment no severe concurrent medical or psychiatric illness no a known hypersensitivity to the study drugs none of the patients were pregnant or lactating.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Disease free survival Overall survival	—

Countries

Japan

Contacts

Public ContactKiyoshi Maeda

Osaka City University Graduate School of Medicine Dept of Surgical Oncology

m1378386@med.osaka-cu.ac.jp06-6645-3838

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026